Concepedia

Pat Larson

PL

Statistics

Publications

3

Citations

119

H-Index

3

Active since

2000

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Thomas Jefferson University

Pat Larson is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacodynamics.

Publications per year

2000–2001

3

Publications

3

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.

Howard Greenberg, Keith Gottesdiener, Martha Huntington et al. · PubMed · 2000 · 69 citations

, , +14

A New Cyclooxygenase‐2 Inhibitor, Rofecoxib (VIOXX®), Did Not Alter the Antiplatelet Effects of Low‐Dose Aspirin in Healthy Volunteers

Howard Greenberg, Keith Gottesdiener, Martha Huntington et al. · The Journal of Clinical Pharmacology · 2000 · 37 citations

, , +10

Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers

Jules I. Schwartz, Marina De Smet, Pat Larson et al. · The Journal of Clinical Pharmacology · 2001 · 13 citations

, , +10

1–3 of 3